Search

Jeremy T Blitzer

from Sunnyvale, CA
Age ~48
Get Report
Related to:
Helene P BlitzerBennett BlitzerAnnette M BlitzerAdam R Blitzer, 44Abraham L Blitzer
Connected to:
Adrienne R Blitzer, 63Gene E Blitzer, 64Ronn M Blitzer, 41David S Blitzstein, 70Joshua A Blitzstein, 43Richard J Blitzstein, 68Andrew S Bliven, 41Cedar S Bliven, 42Janet A Bliven, 63Ken M Bliven, 81

Jeremy Blitzer Phones & Addresses

  • 868 Rosemary Ter, Sunnyvale, CA 94086 (408) 685-2924 (408) 962-0376
  • 1000 Escalon Ave, Sunnyvale, CA 94085 (408) 746-5695
  • 229 Brannan St, San Francisco, CA 94107 (415) 974-1560
  • Stanford, CA
  • 9775 Fox Hollow Ln, Cincinnati, OH 45243
  • Santa Clara, CA
  • 868 Rosemary Ter, Sunnyvale, CA 94086

Work

Position: Professional/Technical

Education

Degree: High school graduate or higher

Resumes

Resumes

Jeremy Blitzer Photo 1

Co-Founder And Managing Director

View page
Location:
San Francisco, CA
Industry:
Biotechnology
Work:
Celmune Therapeutics
Co-Founder and Managing Director
Viba Therapeutics
Co-Founder, Director, and Chief Science
Centaurus Therapeutics
Co-Founder, Director, and Chief Strategy Officer
Potrero Hill Therapeutics
Co-Founder and Managing Director
Biopharma R&D Consulting
Consultant
Education:
Stanford University 2010 - 2014
Doctor of Medicine, Doctorates, Doctor of Philosophy Stanford University Sep 1999 - Jun 2007
Doctor of Medicine, Doctorates, Doctor of Philosophy
Skills:
Entrepreneurship
Technology Transfer
Fda
Drug Discovery
Business Development
Product Development
Drug Development
Pharmacology
Toxicology
Business Strategy
Clinical Trials
Regulatory Affairs
Strategy
Cro
R&D
Pharmaceutical Industry
Life Sciences
Jeremy Blitzer Photo 2

Jeremy Blitzer

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
Jeremy Blitzer
Vice-President
Synamem Corporation
Noncommercial Research Organization
863 Mitten Rd, Burlingame, CA 94010
(650) 259-5000
Jeremy Blitzer
Vice-President, Principal
Synergenics LLC
Nonclassifiable Establishments · Noncommercial Research Organization · Biotech Business Development · Biotechnology Research & Development
1 Market St, San Francisco, CA 94105
1700 Owens St, San Francisco, CA 94158
1 Market, San Francisco, CA 94105
(415) 554-8170

Publications

Us Patents

Methods Of Treating Pain With Mgbg

View page
US Patent:
8609734, Dec 17, 2013
Filed:
Jul 24, 2012
Appl. No.:
13/556948
Inventors:
John McKearn - Saint Louis MO, US
Jeremy Blitzer - San Francisco CA, US
Assignee:
Pathdogica, LLC - Burglingame CA
International Classification:
A61K 31/155
US Classification:
514632, 514870
Abstract:
Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.

Membrane-Coated Particles

View page
US Patent:
20110097819, Apr 28, 2011
Filed:
Mar 16, 2009
Appl. No.:
12/922993
Inventors:
John T. Groves - Berkeley CA, US
Jeremy T. Blitzer - Sunnyvale CA, US
International Classification:
G01N 33/567
US Classification:
436503
Abstract:
A membrane-coated particle composition and methods comprising a particle surrounded by a native cell membrane are disclosed. The cell membrane may contain selected receptors or binding components. At least a portion of the receptors or binding components are oriented on the membrane-coated particle in the same or similar orientation as in the native cell membrane. The membrane-coated particle(s) finds use, for example, in contexts of basic research, proteomics, drug discovery, drug delivery, medical diagnostics, and aspects of patient care.

Pharmaceutical For Oral Delivery Comprising Mgbg And Methods Of Treating Disease

View page
US Patent:
20110112199, May 12, 2011
Filed:
Jul 16, 2010
Appl. No.:
12/837753
Inventors:
John McKearn - Saint Louis MO, US
Jeremy Blitzer - Sunnyvale CA, US
Assignee:
PATHOLOGICA LLC - Burlingame CA
International Classification:
A61K 31/155
A61P 19/02
A61P 37/00
A61P 35/00
A61P 17/06
A61P 25/02
US Classification:
514632
Abstract:
Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.

Controlled Release Oral Pharmaceutical Dosage Forms Comprising Mgbg

View page
US Patent:
20120269891, Oct 25, 2012
Filed:
Jan 19, 2012
Appl. No.:
13/354076
Inventors:
John McKearn - Saint Louis MO, US
Jeremy Blitzer - Sunnyvale CA, US
Assignee:
PATHOLOGICA LLC - Burlingame CA
International Classification:
A61K 9/48
A61K 31/155
A61P 29/00
C07C 281/16
US Classification:
424463, 564227, 514632
Abstract:
Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.

Pharmaceutical For Oral Delivery Comprising Mgbg And Methods Of Treating Disease

View page
US Patent:
20140051765, Feb 20, 2014
Filed:
Oct 25, 2013
Appl. No.:
14/063541
Inventors:
John McKearn - Saint Louis MO, US
Jeremy Blitzer - San Francisco CA, US
Assignee:
PATHOLOGICA LLC - Burlingame CA
International Classification:
A61K 31/155
US Classification:
514632
Abstract:
Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.

Controlled Release Oral Pharmaceutical Dosage Forms Comprising Mgbg

View page
US Patent:
20210085625, Mar 25, 2021
Filed:
Dec 4, 2020
Appl. No.:
17/111895
Inventors:
- San Francisco CA, US
Jeremy BLITZER - San Francisco CA, US
International Classification:
A61K 31/155
C07C 251/12
C07C 251/78
C07C 243/16
C07C 211/13
A61K 9/48
A61K 9/28
A61K 9/50
A61K 9/20
Abstract:
Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.

Inhibitors Of Dihydroceramide Desaturase For Treating Disease

View page
US Patent:
20200339535, Oct 29, 2020
Filed:
Jan 11, 2019
Appl. No.:
16/959807
Inventors:
- San Francisco CA, US
Jeremy Blitzer - San Francisco CA, US
International Classification:
C07D 401/12
C07D 401/14
C07D 405/12
C07D 213/75
C07D 401/04
C07D 241/04
C07D 213/76
Abstract:
Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic disorders, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.

Novel Monoclonal Antibodies To Osteopontin

View page
US Patent:
20190367602, Dec 5, 2019
Filed:
Dec 12, 2017
Appl. No.:
16/468634
Inventors:
- San Francisco CA, US
Jeremy BLITZER - San Francisco CA, US
International Classification:
C07K 16/24
C12N 5/0781
G01N 33/68
Abstract:
The present disclosure relates to the development of antibodies that are targeted to disease specific function directing regions of osteopontin. Such antibodies are capable of binding osteopontin and of selectively blocking one or more functions of osteopontin. In one aspect, the disclosures are based on the discovery that such antibodies spontaneously occur in certain diseases, and have therapeutic utility for the treatment of one or more osteopontin related diseases, where they are capable of selectively blocking the role of osteopontin in disease progression.
Control profile
Jeremy T Blitzer from Sunnyvale, CA, age ~48 Get Report